Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed
comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in
the treatment of Parkinson's disease (PD) patients who continue to have dyskinesia on
amantadine.
Phase:
Phase 2
Details
Lead Sponsor:
Rush University Medical Center
Collaborator:
Michael J. Fox Foundation for Parkinson's Research